Prince Pharmaceutical Co (ROCO:6935) Debt-to-EBITDA : 5.17 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Prince Pharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Prince Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$66.8 Mil. Prince Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$423.6 Mil. Prince Pharmaceutical Co's annualized EBITDA for the quarter that ended in Dec. 2023 was NT$94.9 Mil. Prince Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 5.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Prince Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

ROCO:6935' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -67.58 Med: 5.56 Max: 29.28
Current: 5.56

During the past 5 years, the highest Debt-to-EBITDA Ratio of Prince Pharmaceutical Co was 29.28. The lowest was -67.58. And the median was 5.56.

ROCO:6935's Debt-to-EBITDA is ranked worse than
82.14% of 655 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs ROCO:6935: 5.56

Prince Pharmaceutical Co Debt-to-EBITDA Historical Data

The historical data trend for Prince Pharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prince Pharmaceutical Co Debt-to-EBITDA Chart

Prince Pharmaceutical Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

29.28

-67.58

13.02

4.17

5.56

Prince Pharmaceutical Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial			8.27	3.96	4.80	6.21	5.17

Competitive Comparison of Prince Pharmaceutical Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Prince Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Prince Pharmaceutical Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Prince Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Prince Pharmaceutical Co's Debt-to-EBITDA falls into.

Prince Pharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Prince Pharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(66.765	+	423.595)	/	88.185
	=	5.56

Prince Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(66.765	+	423.595)	/	94.888
	=	5.17

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.

Prince Pharmaceutical Co (ROCO:6935) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Prince Pharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Prince Pharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Prince Pharmaceutical Co (ROCO:6935) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prince Pharmaceutical Co Ltd (ROCO:6935) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Number 168, Keyunnan Road, Huwei Town, Yunlin, TWN, 632

Website

https://www.prince-pharm.com.tw

Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe, and other regions.

Prince Pharmaceutical Co (ROCO:6935) Headlines

No Headlines